The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | FORTE: KRd versus KCd treatment for myeloma
Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the randomized FORTE trial (NCT02203643) investigating the survival of newly diagnosed transplant-eligible patients with multiple myeloma. The study compared progression-free survival (PFS) outcomes from three treatment regimens: carfilzomib-lenalidomide-dexamethasone (KRd) induction or carfilzomib-cyclophosphamide-dexamethasone (KCd) induction followed by autologous stem-cell transplantation (ASCT) and KRd or KCd consolidation, respectively, versus 12 cycles of KRd only (KRd12). The results showed treatment with KRd-ASCT significantly improved the PFS compared to KCd-ASCT and KRd12. A second randomization was then conducted to either KR or R maintenance therapy. KR was shown to be superior to R, resulting in a higher rate of conversion to measurable residual disease negativity and longer PFS. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
